Meticulously selected by Accell, Russian sites twice outperformed enrollment in Western European sites and 6 times in US sites.
Phase III clinical trial in cardiology for a global top-10 pharmaceutical company. Accell recruited 130% of promised patients before the deadline for patient recruitment.
After 16 months of slow recruitment, Sponsor addressed Accell to add an emergency country to rescue the study. Accell recruited 21.6% of total patients in just 6 months.
Accell recruited 84% of total patients, with only 65% of a total number of study sites, and made sure the Sponsor ended recruitment earlier than planned and faster entered the market.